Overcoming Clinical Challenges in BRIC Markets - Russia
Thomson Reuters Cortellis Competitive Intelligence
Read the first installment of this report on Brazil here.
Figure 3A:
Current clinical trial approval timelines in Russia average three to four months. However, unethical conduct in the country has been revealed in surveys and remarks by sponsors. Biogen Idec provided an example at the global clinical trials conference: in 2013, the company shut down all Russian sites for a Phase II trial—representing one quarter of the study’s patients—because investigators did not want their trial income reported to the state employers. Although it does not appear that global sponsors are largely pulling out of Russia, clinical trial initiation has declined in number since its peak in 2012.
SOURCE: Thomson Reuters Cortellis Competitive Intelligence
Read the full report here.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
